<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348838</url>
  </required_header>
  <id_info>
    <org_study_id>PI2019_843_0023</org_study_id>
    <nct_id>NCT04348838</nct_id>
  </id_info>
  <brief_title>Prospective Cohort of Patients With Hepatocellular Carcinoma in France</brief_title>
  <acronym>CHIEF</acronym>
  <official_title>Prospective Cohort of Patients With Hepatocellular Carcinoma in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biobanque de Picardie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Nationale Française de Gastroentérologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association Française pour l’Etude du Foie (AFEF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association Nationale des Hépato-Gastroentérologues des Hôpitaux Généraux (ANGH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Club de Réflexion des Cabinets et Groupes d’Hépato-Gastroentérologie (CREGG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association de Chirurgie Hépato-Bilio-Pancréatique et de Transplantation (ACHBT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Française de Pathologie (SFP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Française de Radiologie (SFR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Societe Francaise de Radiotherapie Oncologique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) occurs in 90% of cirrhosis primary liver cancers. In France,
      8,500 new cases of HCC occur each year, and about 8,000 deaths per year are related to this
      cancer. The 5-year survival rate is 10%, one of the lowest survival rates of all cancer
      types. HCC raises a number of major challenges: HCC is discovered at a curable stage in only
      25% of cases, reflecting the marked delay in the diagnosis of early stages. The state of
      knowledge about HCC is well behind that of other cancers (no biomarker, complex
      carcinogenesis, influence of the aetiology, poorly valorised data, etc.). Rapid technological
      progress requires large-scale studies to evaluate new diagnostic and therapeutic modalities.

      The CHIEF project constitutes a common basis knowledge for research project using
      prospectively collected data in patients with HCC, regardless of the cause and stage of the
      cancer.

      This project is a Multicentre longitudinal observational study of patients with HCC with
      prospective data collection on inclusion and patient follow-up. Constitution of a biological
      resources collection. 5,000 patients will be included over 2 years with a follow-up of
      patients of 5 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of progression free survival (PFS) in intent to treat after liver transplantation</measure>
    <time_frame>from day 1 of inclusion, up to 5 years</time_frame>
    <description>Variation of progression free survival (PFS) in intent to treat after liver transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of time until failure of the strategy after hepatic resection and percutaneous destruction</measure>
    <time_frame>from day 1 of inclusion, up to 5 years</time_frame>
    <description>Variation of time until failure of the strategy after hepatic resection and percutaneous destruction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of overall survival time (OS) after chemoembolization</measure>
    <time_frame>from day 1 of inclusion, up to 5 years</time_frame>
    <description>Variation of overall survival time (OS) after chemoembolization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of overall survival time (OS) after radioembolization</measure>
    <time_frame>from day 1 of inclusion, up to 5 years</time_frame>
    <description>Variation of overall survival time (OS) after radioembolization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of overall survival time (OS) after pharmaceutical treatment</measure>
    <time_frame>from day 1 of inclusion, up to 5 years</time_frame>
    <description>Variation of overall survival time (OS) after pharmaceutical treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of adverse event rate of HCC treatments in clinical practice</measure>
    <time_frame>from day 1 of inclusion, up to 5 years</time_frame>
    <description>Variation of adverse event rate of HCC treatments in clinical practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of serious adverse event rate of HCC treatments in clinical practice</measure>
    <time_frame>from day 1 of inclusion, up to 5 years</time_frame>
    <description>Variation of serious adverse event rate of HCC treatments in clinical practice</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Cancer of Liver</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Hepatic tissues, blood, urine and stools
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population is including new case patients of HCC regardless of the cause, stage of the
        disease and treatment, and patients with known HCC.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New cases of HCC

          -  suspected case of HCC regardless of the cause, stage, treatment

          -  Known HCC: drug treatment for recurrence or progression

        Exclusion Criteria:

          -  Associated serious condition threatening life in the short term (with the exception of
             liver disease itself)

          -  So-called vulnerable populations: minors, persons under guardianship or temporary
             guardianship, or person deprived of their liberty by an administrative or judicial
             decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude BARBARE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves-Edouard HERPE</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Ganry, Pr</last_name>
    <phone>(33)322668193</phone>
    <email>ganry.olivier@chu-amiens.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gérard DUCOURNAU, Ing</last_name>
    <phone>(33)322088376</phone>
    <email>ducournau.gerard@chu-amiens.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Ganry, Pr</last_name>
      <phone>(33)322668193</phone>
      <email>ganry.olivier@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>liver</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>cohort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

